Biosurgery Market By Product Type (Hemostatic Agents, Surgical Sealants and Adhesives, Bone-Graft Substitutes, Soft Tissue Attachments, Adhesion Barriers, Staple Line Reinforcement Agents), By Application (Orthopedic Surgery, Cardiovascular Surgery, Neurological Surgery, General Surgery, Thoracic Surgery, Others), By Source (Biological Products, Synthetic Products), By End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Biosurgery Market in the coming years?

The Biosurgery Market accounted for USD 17.51 Billion in 2024 and USD 18.88 Billion in 2025 is expected to reach USD 40.2 Billion by 2035, growing at a CAGR of around 7.85% between 2025 and 2035. The Biosurgery Market encompasses a part of surgical care involving biological products, which may include hemostatic agents, sealants, adhesives, and anti-adhesion barriers that contribute to surgical care and enhance healing. The market is growing fast because there has been a surge in the number of surgeries around the world, there has been an increase in the adoption of minimal surgery procedures, and post-operative recovery is also increasing the demand.

The most important trends affecting the growth of the market are in the fields of technology in biomaterials, in combination with regenerative medicine, and the production of synthetic and recombinant products. There is also further demand due to the aging populations, traumas, and the burden of chronic diseases. Future focus includes customized biosurgical solutions, machine-assisted operative treatment, and cutting-edge cell-made products. 

What do industry experts say about the Biosurgery Market trends?

“At MJFF, our mission is to accelerate breakthroughs for people living with Parkinson’s by funding diverse and innovative approaches. Grifols’ research on a plasma-based biomarker to detect PD at its earliest stage before progression begins aims to help us understand the biology of individuals who may be at risk and paves the way for transformative breakthroughs in care and prevention.”

• Shalini Padmanabhan, Senior Vice President of Translational Research at the Michael J. Fox Foundation

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Biosurgery Market?

Will rising surgical volumes globally escalate demand for biosurgical solutions?

The Biosurgery Market is experiencing a very strong surge due to rising surgical interventions being carried out globally. An example is that NHSE reported 115,796 surgical incidents reported to its SSI Surveillance System in FY 2021/2022, with 92,930 incidences of mandatory orthopedic surgery and 22,866 within voluntary categories spread across 13 surgical types. Such data indicates the high surgical load that directly increases the utilization of biosurgical applications like hemostatic agents, tissue sealants, barrier agents that support positive surgical outcomes, and post-surgery cure rates. Moreover, the aging population around the world needs to receive more orthopedic and cardiovascular surgery, which also widens the demand for biosurgery products.

This has facilitated the development of compatible, effective, and patient-friendly products due to technological changes. Surgeons would now favor the use of biologically incorporated products in order to lessen the amount of time of surgery and enhance wound healing. The increase in advanced surgical operations, such as spinal and neurosurgery, also substantially raises the market. In addition, the biosurgery helps to reduce any intraoperative bleeding, postoperative complications, hence its growing application. The other trend that will drive the demand for biosurgery is the availability of healthcare to many people globally, with developing nations especially being a major contributor to surgeries, thus increasing the demand for biosurgery.

Are advancements in biomaterials enhancing safety and efficacy in surgery?

The technological advancement of biomaterials is one of the crucial factors that stimulate the biosurgery market. Formation of next-generation bioabsorbable materials, recombinant proteins, as well as synthetic polymers, has transformed the efficacy of bio-surgical products. These materials improve tissue tolerance, lower infection, and diminish inflammatory reactions. Take the example of NHS-Pox hemostatic patches that were shown to be able to control moderate forms of bleeding of the liver in preclinical tests with an efficacy of 83 to 98 % as compared to TachoSil (25 percent) currently used in practice, which represents a tremendous improvement, but also to Veriset (96 to 100 percent) which also illustrates the power of the new platform of biomaterials.

These forms of innovation mean less complication, faster healing, which is paramount in producing an effectiveness of surgical outcomes. Also, new biomaterials are provided with custom functionality that permits accuracy during sensitive operations such as neurosurgery or spinal surgery. These are designed materials that do not harm the body and last long with little removal surgery. They are more acceptable to hospitals and surgical units. They have an extended shelf life, are easy to store, and store and easier to mount because they result in lower immunogenicity. Moreover, the issues of nanomaterials and hydrogel-related technologies are coming out with innovations at a high rate, which increases the biosurgery product range and supports the market growth pattern.

Does the high cost of biosurgical products limit widespread hospital usage?

The cost of the bio-surgical products is one of the greatest market restraints on the Biosurgery Market because it reduces its rate of adoption, particularly in the cost-pressure and resource-constrained healthcare settings. Such sophisticated products tend to include recombinant technologies, unique production methods, or foods of biological origin, all of which are factors in higher prices. Investments in such expensive surgical aids may not be an option in hospitals that operate within a tight budget, especially in low and middle-income countries. In developed markets, the usage of some of the biosurgical materials may not be fully reimbursed by the insurance companies, and, therefore, would not be as popular among ordinary surgical operations.

Such problems with costs are even more important when several biosurgical tools must be used during the operation. The initial cost of these products also, at times, supersedes perceived clinical advantages, especially in normal surgeries where they are still being effectively carried out using original means. Moreover, the expenses of the training and special surgical instruments to apply the products of biosurgery increase the financial burden. Due to this, most hospitals remain attached to the traditional sutures or staples, or low-priced substitutes, and this makes the market potential slow. The Biosurgery Market should also take care of the price difference problem and make it as cost-effective as possible to facilitate its wider adoption in all levels of healthcare.

Can emerging economies present growth potential with rising healthcare investments?

Biosurgery Market is in a good position to open up huge potential in the emerging economies, where the healthcare infrastructure is improving at a high rate, courtesy of the increasing government investments and the participation of the private sector. The world is also observing a booming hospital infrastructure along with medical device availability and skilled surgeons in countries like India, Brazil, China, and various Southeast Asian and African countries. Such trends are helping establish a favorable condition regarding the usage of high-tech biosurgical products. Since the surgical loads are on the increment in these areas, so will be the requirements of efficient as well as effective surgical accessories.

Additionally, increased awareness in the arena of postoperative care, low invasive techniques, and better patient outcomes are stimulating the growing interest in biosurgery. Biosurgery is also becoming affordable in cost-sensitive markets through local manufacturing initiatives, Vietnam DDRGO, generalization in insurance, etc. These regions have become the new target points of global manufacturers, pursuing global manufacturers and cost-optimized products that meet local clinical requirements. These rapidly developing economies allow the Biosurgery Market to assume a leading position and strategic partnerships. Also, being able to overcome regulatory reforms and incentives in imports and exports is favorable to the business case for the expansion to said territories.

Will tissue engineering innovations lead to next-gen personalized biosurgery tools?

Biosurgery and tissue engineering offer an opportunity to revolutionize the Biosurgery Market. As 3D bioprinting, stem cell therapy, and tissue healing on scaffold advances progress, biosurgery is making personalized and regenerative choices that are scarcely consistent with individual patients. The innovations enable the creation of tailor-made biological implants, intelligent glues sensitive to the calls of the tissues, and biomaterials that are becoming part of the body. An example is that in the future, we may have biosurgical sealants that may contain embedded growth factors or stem cells to promote healing. Similarly, bioengineered bone grafts and other cartilage replacements are phasing out the conventional implants.

Such a customized strategy leads to higher success rates in surgery, the decreased likelihood of getting infected, and the lowered necessity of re-surgery. A lot of investment is going on by the hospitals and research institutions in the area of R&D, which has shortened the gap between tissue engineering and biosurgical intervention. Moreover, regulatory boards are now moving to accelerate the approval process of breakthrough products in both fields of scientific event combination. The more clinical support there is around the notion of personalized biosurgery, the more full-fledged acceptance there will be among the surgeons and patients. Biosurgery Market is on the edge of this wave of innovation, and it will have the potential to change the approach and management of complex surgeries in the future.     

What are the key market segments in the Biosurgery industry?

Based on the Product Type, the Biosurgery Market has been classified into Hemostatic Agents, Surgical Sealants and Adhesives, Bone-Graft Substitutes, Soft Tissue Attachments, Adhesion Barriers, Staple Line Reinforcement Agents. The Hemostatic Agent product is dominating the market. These are mainly used in the control of bleeding in surgery and, as such, are essential in high blood loss procedures.

The market for hemostatic agents in demand is increasing because of accurate efficacy, simplicity in application, and speed in action. Another substantial category is surgical sealants and adhesives that have been particularly prevalent in minimally invasive and cardiovascular procedures. The orthopedic and abdominal surgeries, respectively, are embracing bone-graft substitutes and adhesion barriers. 

Based on the Application, the Biosurgery Market has been classified into Orthopedic Surgery, Cardiovascular Surgery, Neurological Surgery, General Surgery, Thoracic Surgery, and Others. Orthopedic Surgery can be considered as the leading segment in the Biosurgery Market due to the abundance of procedures performed in the form of joint replacements and spinal procedures throughout the world. Such operations need hemostatic remedies, bone-graft alternatives, and tissue adhesives to improve their results.

Next on the list are the cardiovascular and general surgeries, which are supported by the aging population, and the surge in cardiac and abdominal problems. Neurological and thoracic surgeries are very significant markets where biosurgical products are being used to enhance accuracy and minimize complications. 

Which regions are leading the Biosurgery Market, and why?

The North America Biosurgery Market is presently led by due to the excellent healthcare facilities, elevated surgical procedures, as well as impressive penetration of cutting-edge healthcare technologies. The region enjoys the existence of key players in the market, including Johnson & Johnson, Baxter, and Medtronic, who engage in a high level of investment in research and development and product launches. Widespread use of biosurgical products is assisted by high levels of awareness among surgeons, positive reimbursement policy, and well-developed hospital networks.

Moreover, the growing number of the elderly and the growing rates of chronic illness increase the demand as well. North America has a major stake in the industry, with the USA taking the lion's share, followed by the other countries in the continent, because it has a large patient market and upbeat surgical facilities, putting it in the lead position across the globe in the Biosurgery Market.

The Asia-Pacific Biosurgery Market is the fastest growing region, which is driven due to lightning advancements in healthcare facilities and a rising number of surgeries in countries such as China, India, and South Korea. Increased government expenditure on healthcare, the rise in the volume of medical tourism, and the proliferation of private hospital chains are all contributing to the provision of high-quality surgical services.

Besides, the development of awareness of minimally invasive surgeries and the follow-up care is quickening the rate of adoption of biosurgery products. There are also cost-effective and regionally customized solutions that manufacturers are eyeing in this region. Asia-Pacific has huge potential yet untapped due to its large population base; high disposable incomes are increasing its stature as a major growth center of the global Biosurgery Market.  

What does the competitive landscape of the Biosurgery Market look like?

Biosurgery Market thrives in a very concentrated competitive environment with the major players consolidated on a global basis with a massive share of the product portfolio, an excellent distribution chain, and consistent innovations. Some of the major competitors are Johnson & Johnson (Ethicon), Baxter International, Medtronic, Becton, Dickinson and Company, Stryker Corporation, Integra LifeSciences, CSL Behring, and Smith & Nephew. Such firms are engaged in strategies of acquiring and merging, product launch, geographical expansion, and investments in R&D as a tool to enhance their positions in the market. Johnson & Johnson maintains its leadership by offering a wide range of surgical solutions, whereas Baxter focuses on the expansion of its portfolio in hemostatic agents and sealants.

Medtronic is also trying to bring together biosurgery and sophisticated surgical medical devices to enhance clinical outcomes. Smaller-scale companies such as CryoLife and Arch Therapeutics are interested in niche innovation and FDA approvals in order to obtain a competitive advantage. Working with hospitals and surgical centers, as well as increased interest in personalized and regenerative surgical products, are major strategies in every respect. Competition is also rising in the emerging economies, and in such a market, customization and affordability are most important.

Biosurgery Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Biosurgery industry?

• In October 2024, Grifols won FDA approval for its plasma-protein fibrin sealant for pediatric use in controlling surgical bleeding, widening its market into younger populations. This milestone positions Grifols as a key player in pediatric biosurgical solutions with expanded clinical relevance.
• In March 2024, Baxter International launched a novel hemostatic product offering rapid and sustained bleeding control across diverse surgical settings, emphasizing efficiency and safety. The product aims to reduce operative time and improve patient outcomes in both open and minimally invasive procedures.

Report Coverage:

By Product Type

• Hemostatic Agents
• Surgical Sealants and Adhesives
• Bone-Graft Substitutes
• Soft Tissue Attachments
• Adhesion Barriers
• Staple Line Reinforcement Agents

By Application

• Orthopedic Surgery
• Cardiovascular Surgery
• Neurological Surgery
• General Surgery
• Thoracic Surgery
• Others

By Source

• Biological Products
• Synthetic Products

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Johnson & Johnson
• Baxter International Inc.
• Medtronic plc
• Becton, Dickinson and Company
• Stryker Corporation
• Integra LifeSciences Holdings Corporation
• CSL Behring
• Zimmer Biomet Holdings, Inc.
• B. Braun Melsungen AG
• Sanofi
• Hemostasis, LLC
• Pfizer Inc.
• Smith & Nephew plc
• CryoLife, Inc.
• Arch Therapeutics, Inc.

Frequently Asked Questions (FAQs)